IL3 and myeloid sarcoma: Interestingly, IL-3, which was particularly affected after ASC-EV administration (p = 0.0317), has been recently involved in glial–peripheral immune interplay in CNS plaques and correlated to exacerbated MS and EAE pathology (Figure 5A) [42].